![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761378
https://www.pharmiweb.com/press-release/2024-05-15/ms-pharma-becomes-partner-for-the-commercialization-of-fyb203-formycon-s-biosimilar-candidate-to-ey
https://www.pharmiweb.com/press-release/2024-05-08/formycon-reports-on-successful-operating-business-and-financial-figures-for-the-first-quarter-of-202
https://www.fiercepharma.com/pharma/jj-inks-another-stelara-patent-settlement-time-fresenius-kabi-and-formycon
https://www.pharmiweb.com/press-release/2022-11-03/broad-acting-antiviral-sars-cov-2-drug-fyb207-shows-longer-half-life-and-improved-efficacy-through-o
https://www.formycon.com/en/press-release/formycon-publishes-details-of-a-previously-undisclosed-pipeline-project-fyb206-is-a-biosimilar-candidate-for-keytruda-pembrolizumab/
https://www.pharmatimes.com/news/european_commission_approves_pharma_trios_ranivisio_1454045
https://www.contractpharma.com/contents/view_breaking-news/2022-08-03/fda-approves-first-biosimilar-to-lucentis/?widget=listSection
https://www.lexblog.com/2022/05/19/teva-receives-approval-for-first-ophthalmology-biosimilar-in-europe/
https://generics.pharmaintelligence.informa.com/GB151893/Whos-Hired-Formycon-Is-Latest-To-Swap-CEO